Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18126629 | 0.81 | PPARG (0.57) | KMOPPARGPPARDPPARAOXER1 | |
| SCHEMBL22005106 | 0.81 | ACLY (0.49) | ACLYABCB11PTGS2KMOPHGDH | |
| SCHEMBL25777909 | 0.80 | PPARG (0.56) | KMOPPARGPPARDPPARAOXER1 | |
| SCHEMBL18112916 | 0.80 | RXFP1 (0.47) | RXFP1PHGDHPPARGPPARDPPARA | |
| SCHEMBL9679406 | 0.79 | KDM4E (0.62) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL30042365 | 0.79 | MCL1 (0.57) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2343924 | 0.79 | MCL1 (0.57) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2643465 | 0.76 | RXFP1 (0.60) | RXFP1PHGDHMEN1KMT2AKDM4E | |
| SCHEMBL43328 | 0.76 | KDM4E (0.66) | RXFP1PHGDHMEN1KMT2AKDM4E | |
| SCHEMBL1253867 | 0.74 | RXFP1 (0.44) | RXFP1PHGDHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885ABCB11 390/4885PTGS2 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.